These results could indicate the usefulness of potential therapeutics targeting ADAM10 or ADAM17, which cleave CX3CL1, to prevent the formation of excessive soluble CX3CL1 as a means to modify disease outcome for tauopathies. Here, CX3CL1 is linked to tauopathy.